Evidence map›Paper›PMID 35463333›Full record

ArticleFrontiers in oncology2022

Epidemiological and Clinical Characteristics of Five Rare Pathological Subtypes of Hepatocellular Carcinoma.

Xiaoyuan Chen, Yiwei Lu, Xiaoli Shi, Guoyong Han, Long Zhang, Chuangye Ni, Jie Zhao, Yun Gao, Xuehao Wang

Open access · goldAbstract read
In one paragraph

Article in Frontiers in oncology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
1.8field-weighted citation impact, top 15% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 1 country.

Xiaoyuan ChenHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yiwei LuHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xiaoli ShiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Guoyong HanHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Long ZhangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Chuangye NiHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Jie ZhaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Yun GaoHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Xuehao WangHepatobiliary Center, The First Affiliated Hospital of Nanjing Medical University, Nanjing, China.
Nanjing Medical University · CNJiangsu Province Hospital · CNChinese Academy of Medical Sciences & Peking Union Medical College · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Background: Hepatocellular carcinoma (HCC) is a highly heterogeneous tumor with several rare pathological subtypes and which is still poorly understood. This study aimed to describe the epidemiological and clinical spectrum of five rare HCC subtypes and develop a competing risk nomogram for cancer-specific survival prediction. Methods: The study cohort was recruited from the Surveillance, Epidemiology, and End Results database. The clinicopathological data of 50,218 patients histologically diagnosed with classic HCC and five rare subtypes (ICD-O-3 Histology Code = 8170/3-8175/3) between 2004 and 2018 were reviewed. The annual percent change (APC) was calculated utilizing Joinpoint regression. The nomogram was developed based on multivariable competing risk survival analyses. Akaike information criterion, Bayesian information criterion, C-index, calibration curve, and area under the receiver operating characteristic curve were obtained to evaluate the prognostic performance. A decision curve analysis was introduced to examine the clinical value of the models. Results: Despite scirrhous carcinoma, which showed a decreasing trend (APC = -6.8%, Conclusion: The rare subtypes had unique clinicopathological features and biological behaviors compared with the classic HCC. Our findings could provide a valuable reference for clinicians. The constructed nomogram could predict the prognoses with good performance, which is meaningful to individualized management.

Indexed as

clear cell carcinomafibrolamellar carcinomahepatocellular carcinomapathological subtypepleomorphic carcinomascirrhous carcinomaspindle cell carcinomaThe SEER Program

Identifiers

PMID35463333
PMCPMC9026181
OpenAlexW4225794786

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.